Bajaj Healthcare Ltd
NSE: BAJAJHCARE BSE: 539872Pharma
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
₹275
52W: ₹272 — ₹609
PE 19.7 · Book ₹158 · +74% vs bookMarket Cap₹926 Cr
Stock P/E19.7Price to Earnings
ROCE11.5%Return on Capital
ROE9.4%Return on Equity
Div. Yield0.35%Face Value ₹5
Weaknesses
- −Promoter holding has decreased over last quarter: -0.90%
- −The company has delivered a poor sales growth of -1.44% over past five years.
- −Company has a low return on equity of 3.96% over last 3 years.
- −Dividend payout has been low at 1.57% of profits over last 3 years
Shareholding Pattern
Promoters58.29%
FIIs1.98%
DIIs2.91%
Public36.82%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 67.74% | 59.19%▼8.5 | 59.19% | 59.19% | 59.19% | 59.19% | 59.19% | 58.29%▼0.9 |
| FIIs | 0% | 1.07%▲1.1 | 1.01%▼0.1 | 1.05%▲0.0 | 1.09%▲0.0 | 1.12%▲0.0 | 1.18%▲0.1 | 1.98%▲0.8 |
| DIIs | 0% | 1.97%▲2.0 | 2.36%▲0.4 | 2.52%▲0.2 | 3.16%▲0.6 | 2.99%▼0.2 | 2.96%▼0.0 | 2.91%▼0.0 |
| Public | 32.27% | 37.77%▲5.5 | 37.45%▼0.3 | 37.25%▼0.2 | 36.56%▼0.7 | 36.7%▲0.1 | 36.67%▼0.0 | 36.82%▲0.1 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 109 | 134 | 132 | 133 | 123 | 154 | 149 | 148 | 161 | 153 |
| Expenses | 89 | 118 | 108 | 109 | 101 | 143 | 124 | 121 | 131 | 130 |
| Operating Profit | 20 | 16 | 24 | 25 | 22 | 12 | 25 | 27 | 31 | 23 |
| OPM % | 18% | 12% | 19% | 18% | 18% | 8% | 16% | 18% | 19% | 15% |
| Net Profit | -2 | -30 | 7 | 9 | 12 | 11 | 12 | 11 | 16 | -23 |
| EPS ₹ | -0.8 | -10.84 | 2.58 | 3 | 3.71 | 3.54 | 3.75 | 3.52 | 4.96 | -6.79 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹611Cr, up 12.5% YoY. OPM at 17%.
Debt Position
Borrowings at ₹249Cr. Debt-to-equity ratio: 0.48x. Healthy balance sheet.
Capex Cycle
CWIP at ₹8Cr (3% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 2.91% (+2.57pp change). FIIs: 1.98% (+1.29pp change). Promoters hold 58.29%.
Margin & Efficiency
ROCE declining from 16% (Mar 2015) to 11% (Mar 2026). Working capital days: 119.
Valuation
PE 19.7x with 11.5% ROCE. Price is 74% above book value of ₹158. Dividend yield: 0.35%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 May
- Announcement under Regulation 30 (LODR)-Monitoring Agency Report 8 May - CARE report for quarter ended March 31, 2026 shows Rs 204.97 crore preferential issue utilization with no deviation.
- Compliances-Statement Of Deviation & Variation 8 May - Quarter ended 31 March 2026 statement confirms no deviation in preferential issue proceeds.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 8 May - Bajaj Healthcare reported Q4 FY26 results, FY26 revenue up 12.6%, and converted 2,079,409 warrants for ₹527 million.
- Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 8 May - Board approved FY26 audited results, recommended Rs1.50 final dividend, and appointed internal and cost auditors.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse